Avant signs $375K/quarter advisor deal with Timothy Lantz for product & market strategy

AVAI BIO, INC.

Timothy Lantz appointed Chief Product & Market Strategy Advisor effective Aug 1, 2023; receives $375K quarterly (40% cash min, rest in stock at 15% VWAP discount, floor $0.10).
If Avant lists on Nasdaq, quarterly fee increases to $450K retroactive to Aug 1, 2023; payments then in cash.
Term runs Aug 1, 2023 to July 31, 2024, extendable by mutual consent; 30-day termination for convenience by either party.
Advisor currently serves as senior executive at a private AI/tech company; agreement acknowledges outside work.
Shares issued are unregistered; advisor accredited investor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.